Campbell & CO Investment Adviser LLC Sells 16,036 Shares of Harmony Biosciences Holdings, Inc. $HRMY

Campbell & CO Investment Adviser LLC decreased its holdings in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 35.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 28,871 shares of the company’s stock after selling 16,036 shares during the period. Campbell & CO Investment Adviser LLC’s holdings in Harmony Biosciences were worth $796,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of HRMY. New York State Teachers Retirement System grew its holdings in shares of Harmony Biosciences by 8.1% during the 3rd quarter. New York State Teachers Retirement System now owns 34,923 shares of the company’s stock worth $962,000 after acquiring an additional 2,630 shares during the period. State of Alaska Department of Revenue boosted its holdings in Harmony Biosciences by 3.8% in the third quarter. State of Alaska Department of Revenue now owns 23,764 shares of the company’s stock worth $654,000 after acquiring an additional 867 shares in the last quarter. SG Americas Securities LLC grew its stake in shares of Harmony Biosciences by 16.1% in the third quarter. SG Americas Securities LLC now owns 22,884 shares of the company’s stock worth $631,000 after acquiring an additional 3,177 shares during the last quarter. CX Institutional grew its stake in shares of Harmony Biosciences by 10.9% in the third quarter. CX Institutional now owns 230,433 shares of the company’s stock worth $6,351,000 after acquiring an additional 22,650 shares during the last quarter. Finally, CWA Asset Management Group LLC increased its holdings in shares of Harmony Biosciences by 32.6% during the third quarter. CWA Asset Management Group LLC now owns 38,733 shares of the company’s stock valued at $1,067,000 after acquiring an additional 9,514 shares in the last quarter. Institutional investors own 86.23% of the company’s stock.

Analysts Set New Price Targets

HRMY has been the topic of a number of analyst reports. Oppenheimer reiterated an “outperform” rating and issued a $62.00 price target on shares of Harmony Biosciences in a research note on Monday, November 24th. Weiss Ratings restated a “hold (c)” rating on shares of Harmony Biosciences in a report on Monday, December 29th. Truist Financial lowered their price objective on Harmony Biosciences from $48.00 to $45.00 and set a “buy” rating on the stock in a research report on Thursday, January 8th. Deutsche Bank Aktiengesellschaft reduced their target price on Harmony Biosciences from $54.00 to $36.00 and set a “buy” rating for the company in a report on Thursday, September 25th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Harmony Biosciences in a report on Wednesday, December 3rd. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $45.25.

Harmony Biosciences Stock Performance

HRMY stock opened at $36.22 on Tuesday. The company has a debt-to-equity ratio of 0.18, a current ratio of 3.75 and a quick ratio of 3.72. Harmony Biosciences Holdings, Inc. has a 1 year low of $25.52 and a 1 year high of $40.93. The company has a market cap of $2.09 billion, a P/E ratio of 11.39, a price-to-earnings-growth ratio of 0.38 and a beta of 0.84. The stock’s fifty day moving average price is $36.86 and its 200-day moving average price is $34.06.

Harmony Biosciences (NASDAQ:HRMY) last posted its earnings results on Tuesday, November 4th. The company reported $0.87 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.05). The firm had revenue of $239.46 million during the quarter, compared to the consensus estimate of $222.68 million. Harmony Biosciences had a net margin of 22.50% and a return on equity of 24.88%. On average, equities analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.

Insider Buying and Selling

In other Harmony Biosciences news, CEO Jeffrey M. Dayno sold 25,933 shares of the stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $40.11, for a total value of $1,040,172.63. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 23.60% of the company’s stock.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.